Latest Conference Content

Even top academic centers struggle to keep pace with precision medicine, says William K. Oh, MD, who is prioritizing clinician education at Yale.

In part 2, Christine Pfaff, RPh, MBA, explores reimbursement gaps, new payment models, and payer partnerships needed to expand cellular therapy access.

In part 2, Rosa Novo discusses how employers can expand access to cancer screening and why they need a greater voice in shaping cancer care.

AI could ease oncology's drug development "traffic jam," while biomarker subsetting drives more personalized cancer care, David Spigel, MD, says.

Amanda Green, MPH, discusses how employers can improve benefit awareness, care navigation, cancer prevention, and cost strategies.

Debra Patt, MD, PhD, MBA, MPH, discusses how AI can streamline prior authorization and revenue cycle workflows in community oncology.

Chester Good, MD, MPH, shares data and strategies used by UPMC to evaluate value-based contracting in specialty pharmacy.

Advanced primary care, return-to-work support, and survivorship follow-up are key employer cancer strategies, said Karen van Caulil, PhD.

Two posters report 3.9% first-year GLP-1 discontinuation and a 5-day median time to first fill under pharmacist-led care.

Community oncologists cited prior authorization as a care barrier, even as AI adoption doubled in 2026, according to the Oncology Care Index.

Community oncology faces high costs and staffing hurdles for trials; Lucio N. Gordan, MD, urges pragmatic designs matching real-world patients.

In part 2, David Johnson, MD, MPH, discusses how real-time data can sustain gold carding, ease prior authorization burden, and ensure accountability.

Panelists say IRA, Most Favored Nation rules and fragmented data are freezing value-based deals for durable one-time therapies.

Adaolisa Anaka, PharmD, BCACP, AAHIVP, discusses a pharmacist-led model that targets access barriers to GLP-1 obesity therapy.

Payers say NCCN guideline concordance sets a baseline for cancer coverage, but cost and formulary variation may still limit access.

Liquid biopsy and at-home phlebotomy are closing precision medicine access gaps nationwide, though tissue remains the gold standard.

At NASP's inSPire2026, covered entities and manufacturers debate 340B program reform, contract pharmacies, and the 2027 rebate model.

Irfana Lakada, PharmD, CSP, explains why onboarding may be the wrong time to screen for social needs and why rescreening matters.

Jesse Dresser explains how federal PBM reform, a new CMS RFI, and FTC settlements could reshape specialty pharmacy contracts and pay from 2027.

Accelerated approvals, surrogate end points, and high drug costs are reshaping cancer center formulary decisions, explained panelists at PCOC.

Karen van Caulil, PhD, explained why employers evaluating cancer care weigh timely access, quality, and equity alongside cost.

Stephen "Fred" Divers, MD, discusses how COA study data push back on payer bias and support community oncology's long-term sustainability.

Physicians to Discuss 2026 Oncology Care Index at Patient-Centered Oncology Care®, Premier Annual AJMC® Event Starting Today in Nashville | 60% of Community Physicians Say Clinical Trial Options Are Limited; 93% Say Pragmatic Designs Would Help

Panelists at NASP inSPire2026 said specialty pharmacies could close clinical trial enrollment gaps by capturing one missed data point.

David Johnson, MD, MPH, discusses how payer data can reduce low-value cancer care and steer patients to supportive services and cost-efficient sites.

Medicare's cell and gene therapy payment gap remains, with hospitals absorbing costs as insurers limit coverage.

Stephen “Fred” Divers, MD, discusses findings showing community oncology delivers outcomes comparable with academic care for breast cancer and NSCLC.

Stephen "Fred" Divers, MD, previews PCOC 2026, including his session on the Oncology Care Index and the gap in AI adoption in oncology.